MADRIGAL PHARMACEUTICALS INC
MDGLNASDAQ🏆 #671 by market capEarnings Nov 2 · PreUS Equity
$435.69▼ $13.38 (−3.07%)
Simulated price1h—
24h▼ 3.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$11.91B
Mid Cap
📈Revenue Growth (YoY)
+149.0%
High Growth
📊Gross Margin
91.5%
High
💵FCF Margin
7.4%
Moderate
⚖️P/S Ratio
9.3x
Elevated
Otter Score
50
Weak
No chart data available for MDGL.
Trading Snapshot
- Day Range
- $430.74 – $443.99
- 52-Week Range
- $339.31 – $615.00
- Volume
- $3.66B
- Avg Volume
- $2.66B
- Shares Outstanding
- 23.1M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.28B
- Last Q Revenue
- $307M
- P/E Ratio
- —
- P/S Ratio
- 9.3x
- EPS (TTM)
- $-12.87
- Dividend Yield
- —
Why Investors Own MDGL
- ✓High-growth profile — revenue up -4.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$1.28B▼ −3.9% YoY
Gross Margin (TTM)
29.8%▲ +3.6% YoY
Operating Income (TTM)
$331M▼ −3.9% YoY
Free Cash Flow (TTM)
$370M▼ −3.9% YoY
About MADRIGAL PHARMACEUTICALS INC
A company profile for MADRIGAL PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Price Target
ⓘAverage Target
$544.89
▲ +25.1% Upside
High Target$617.36
Low Target$495.31
Based on 20 analysts
Latest News & Updates
🚀
CNBC·2h ago
MADRIGAL PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift MDGL price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
MADRIGAL PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.